New heart valve study aims to improve treatment for narrowed aortic valve
NCT ID NCT06342635
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a new heart valve called Hydra in 50 people with severe aortic stenosis, a condition where the heart's main valve narrows. The goal is to see if the valve is safe and works well for up to one year after a minimally invasive replacement procedure. Researchers will also use CT scans to understand how the valve's shape affects heart rhythm problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2024
- Expected to finish
-
Oct 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patient with severe aortic valve stenosis
- Ages
-
18 to 99 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age ≥ 18 years 2. Patients affected by severe aortic stenosis (NYHA class ≥ II) eligible for TAVI procedure as per local Heart Team evaluation 3. Full understanding and willing to provide informed consent to study enrolment Exclusion Criteria: 1. Contraindications to TAVI (e.g., anatomically phenotypes, intracardiac mass, thrombus, vegetation, endocarditis) 2. Refusal to provide informed consent to study enrolment 3. Patients with severe aorta or peripheral artery disease precluding transfemoral approach of TAVI 4. Patients with calcification on the annulus and in the Left Ventricular Outflow Tract (LVOT), or/and excess calcium within each cusp, or those who are deemed unsuitable for the Hydra THV series based on the clinical judgment of the Investigator
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Aortic valve stenosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Copenhagen University Hospital, Rigshospitalet
RECRUITINGCopenhagen, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can aggressive blood pressure treatment slow aortic valve disease?
- Why do animal heart valves wear out? immune system under investigation
- One scan to rule them all? new CT aims to replace multiple heart tests
- Which heart valve design wins for small aortic openings?
- Can a less invasive valve replacement tame a failing aortic valve?
- Can a new heart valve match the safety of proven ones?